Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee. The company also develops FX101 and FX201, which is a pre-clinical stage programs for the treatment OA of large joints. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FLXN
CUSIPN/A
Phone781-305-7777
Debt
Debt-to-Equity Ratio0.67
Current Ratio15.57
Quick Ratio15.47
Price-To-Earnings
Trailing P/E Ratio-6.68
Forward P/E Ratio-5.81
P/E GrowthN/A
Sales & Book Value
Annual Sales$350,000.00
Price / Sales2,960.65
Cash FlowN/A
Price / CashN/A
Book Value$6.93 per share
Price / Book3.97
Profitability
EPS (Most Recent Fiscal Year)($4.16)
Net Income$-137,480,000.00
Net MarginsN/A
Return on Equity-72.18%
Return on Assets-39.69%
Miscellaneous
Employees251
Outstanding Shares37,640,000
Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions
What is Flexion Therapeutics' stock symbol?
Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."
How were Flexion Therapeutics' earnings last quarter?
Flexion Therapeutics (NASDAQ:FLXN) posted its quarterly earnings data on Tuesday, May, 8th. The specialty pharmaceutical company reported ($1.10) earnings per share for the quarter, beating analysts' consensus estimates of ($1.33) by $0.23. The specialty pharmaceutical company earned $2.19 million during the quarter, compared to analyst estimates of $1.99 million. View Flexion Therapeutics' Earnings History.
What price target have analysts set for FLXN?
8 analysts have issued 1 year price targets for Flexion Therapeutics' shares. Their forecasts range from $36.00 to $570.00. On average, they expect Flexion Therapeutics' stock price to reach $106.3750 in the next year. View Analyst Ratings for Flexion Therapeutics.
Who are some of Flexion Therapeutics' key competitors?
Some companies that are related to Flexion Therapeutics include Ultragenyx Pharmaceutical (RARE), HUTCHISON CHINA/S (HCM), Array Biopharma (ARRY), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Portola Pharmaceuticals (PTLA), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Emergent Biosolutions (EBS), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT) and Arena Pharmaceuticals (ARNA).
Who are Flexion Therapeutics' key executives?
Flexion Therapeutics' management team includes the folowing people:
- Dr. Michael D. Clayman, Co-Founder, Pres, CEO, Principal Financial & Accounting Officer and Director (Age 66)
- Dr. Neil Bodick M.D., Ph.D., Co-Founder & Chief Scientific Officer (Age 71)
- Mr. Frederick W. Driscoll, Advisor (Age 67)
- Scott Young, Sr. Director of Corp. Communications & Investor Relations
- Ms. Carolyn Beaty Scimemi Esq., Chief Compliance Officer
Has Flexion Therapeutics been receiving favorable news coverage?
Press coverage about FLXN stock has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Flexion Therapeutics earned a media sentiment score of 0.17 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 45.51 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Flexion Therapeutics' major shareholders?
Flexion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.94%), Rubric Capital Management LP (5.38%), Wells Fargo & Company MN (4.46%), Millennium Management LLC (1.84%), Wasatch Advisors Inc. (1.68%) and Schroder Investment Management Group (1.36%). Company insiders that own Flexion Therapeutics stock include Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Institutional Ownership Trends for Flexion Therapeutics.
Which institutional investors are selling Flexion Therapeutics stock?
FLXN stock was sold by a variety of institutional investors in the last quarter, including Bamco Inc. NY, BlackRock Inc., Wasatch Advisors Inc., Wells Fargo & Company MN, JPMorgan Chase & Co., Gagnon Securities LLC, Allianz Asset Management GmbH and Allianz Asset Management GmbH. View Insider Buying and Selling for Flexion Therapeutics.
Which institutional investors are buying Flexion Therapeutics stock?
FLXN stock was bought by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Millennium Management LLC, UBS Group AG, California Public Employees Retirement System, Trexquant Investment LP, Wexford Capital LP, Cubist Systematic Strategies LLC and DekaBank Deutsche Girozentrale. Company insiders that have bought Flexion Therapeutics stock in the last two years include Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Insider Buying and Selling for Flexion Therapeutics.
How do I buy shares of Flexion Therapeutics?
Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Flexion Therapeutics' stock price today?
One share of FLXN stock can currently be purchased for approximately $27.72.
How big of a company is Flexion Therapeutics?
Flexion Therapeutics has a market capitalization of $1.03 billion and generates $350,000.00 in revenue each year. The specialty pharmaceutical company earns $-137,480,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Flexion Therapeutics employs 251 workers across the globe.
How can I contact Flexion Therapeutics?
Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]
MarketBeat Community Rating for Flexion Therapeutics (FLXN)
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe FLXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
